0 3 The the DT 4 21 transcriptionally transcriptionally RB 22 28 active active JJ 29 36 factors factor NNS 37 46 mediating mediate VBG 47 50 the the DT 51 57 effect effect NN 58 60 of of IN 61 64 the the DT 65 71 HTLV-I HTLV-I NNP 72 75 Tax Tax NNP 76 90 transactivator transactivator NN 91 93 on on IN 94 97 the the DT 98 103 IL-2R IL-2R NNP 104 109 alpha alpha NN 110 115 kappa kappa NN 116 117 B B NNP 118 126 enhancer enhancer NN 127 134 include include VBP 135 138 the the DT 139 146 product product NN 147 149 of of IN 150 153 the the DT 154 159 c-rel c-rel NN 160 174 proto-oncogene proto-oncogene NN 174 175 . . . 177 180 The the DT 181 195 transactivator transactivator NN 196 202 HTLV-I HTLV-I NNP 203 206 Tax Tax NNP 207 216 activates activate VBZ 217 220 the the DT 221 229 promoter promoter NN 230 232 of of IN 233 236 the the DT 237 241 gene gene NN 242 248 coding cod VBG 249 252 for for IN 253 256 the the DT 257 268 interleukin interleukin NN 269 270 2 2 CD 271 282 alpha-chain alpha-chain NN 283 291 receptor receptor NN 292 293 ( ( ( 293 298 IL-2R IL-2R NNP 299 304 alpha alpha NN 304 305 ) ) ) 306 309 via via IN 310 311 a a DT 312 317 kappa kappa NN 318 319 B B NNP 320 324 site site NN 325 329 that that WDT 330 333 can can MD 334 338 bind bind VB 339 346 several several JJ 347 354 protein protein NN 355 362 species specie NNS 363 365 of of IN 366 369 the the DT 370 373 rel rel NN 374 380 family family NN 380 381 . . . 382 386 Tax1 Tax1 NNP 387 395 strongly strongly RB 396 405 activates activate VBZ 406 409 the the DT 410 418 enhancer enhancer NN 419 427 activity activity NN 428 430 of of IN 431 435 this this DT 436 441 motif motif NN 441 442 , , , 443 445 in in IN 446 450 both both CC 451 461 epithelial epithelial JJ 462 466 HeLa HeLa NNP 467 470 and and CC 471 479 lymphoid lymphoid JJ 480 486 Jurkat Jurkat NNP 487 492 cells cell NNS 492 493 . . . 494 498 This this DT 499 509 activation activation NN 510 513 was be VBD 514 517 not not RB 518 526 observed observe VBN 527 529 in in IN 530 546 undifferentiated undifferentiated JJ 547 562 embryocarcinoma embryocarcinoma NN 563 565 F9 f9 NN 566 571 cells cell NNS 571 572 . . . 573 587 Overexpression overexpression NN 588 590 of of IN 591 594 the the DT 595 598 p50 p50 NN 598 599 , , , 600 603 p65 p65 NN 604 607 and and CC 608 611 Rel Rel NNP 612 620 proteins protein NNS 621 623 in in IN 624 629 these these DT 630 635 cells cell NNS 636 642 showed show VBD 643 647 that that IN 648 659 significant significant JJ 660 670 activation activation NN 671 673 of of IN 674 677 the the DT 678 683 IL-2R IL-2R NNP 684 689 alpha alpha NN 690 695 kappa kappa NN 696 697 B B NNP 698 702 site site NN 703 706 was be VBD 707 715 observed observe VBN 716 720 only only RB 721 725 with with IN 726 729 Rel Rel NNP 730 733 and and CC 734 737 Rel Rel NNP 738 742 plus plus CC 743 746 p65 p65 NN 746 747 . . . 748 756 Moreover moreover RB 756 757 , , , 758 765 whereas whereas IN 766 770 both both CC 771 774 Tax Tax NNP 775 778 and and CC 779 786 phorbol phorbol NN 787 799 12-myristate 12-myristate NN 800 810 13-acetate 13-acetate NN 811 812 ( ( ( 812 815 PMA PMA NNP 815 816 ) ) ) 817 820 are be VBP 821 825 able able JJ 826 828 to to TO 829 840 efficiently efficiently RB 841 847 induce induce VB 848 851 the the DT 852 859 binding binding NN 860 862 of of IN 863 871 NF-kappa NF-kappa NNP 872 873 B B NNP 874 876 to to TO 877 880 the the DT 881 886 IL-2R IL-2R NNP 887 892 alpha alpha NN 893 898 kappa kappa NN 899 900 B B NNP 901 905 site site NN 905 906 , , , 907 910 PMA PMA NNP 911 913 is be VBZ 914 926 functionally functionally RB 927 935 inactive inactive JJ 935 936 . . . 937 942 Using use VBG 943 946 the the DT 947 950 DNA DNA NNP 951 959 affinity affinity NN 960 973 precipitation precipitation NN 974 979 assay assay NN 979 980 , , , 981 983 we we PRP 984 992 observed observe VBD 993 997 that that IN 998 1002 Tax1 tax1 NN 1003 1005 is be VBZ 1006 1010 able able JJ 1011 1013 to to TO 1014 1025 efficiently efficiently RB 1026 1032 induce induce VB 1033 1036 the the DT 1037 1044 binding binding NN 1045 1047 of of IN 1048 1051 Rel Rel NNP 1051 1052 , , , 1053 1060 whereas whereas IN 1061 1064 PMA PMA NNP 1065 1067 is be VBZ 1068 1071 not not RB 1071 1072 . . . 1073 1077 This this DT 1078 1089 established establish VBD 1090 1091 a a DT 1092 1097 clear clear JJ 1098 1108 difference difference NN 1109 1116 between between IN 1117 1121 both both DT 1122 1129 stimuli stimulus NNS 1129 1130 , , , 1131 1141 indicating indicate VBG 1142 1146 that that IN 1147 1150 Rel Rel NNP 1151 1153 is be VBZ 1154 1157 the the DT 1158 1170 functionally functionally RB 1171 1177 active active JJ 1178 1184 factor factor NN 1184 1185 . . . 1186 1188 We we PRP 1189 1197 conclude conclude VBP 1198 1202 from from IN 1203 1208 these these DT 1209 1216 results result NNS 1217 1221 that that IN 1222 1225 the the DT 1226 1236 functional functional JJ 1237 1245 activity activity NN 1246 1248 of of IN 1249 1256 members member NNS 1257 1259 of of IN 1260 1263 the the DT 1264 1267 rel rel NN 1268 1274 family family NN 1275 1277 is be VBZ 1278 1287 regulated regulate VBN 1288 1290 by by IN 1291 1296 their their PRP$ 1297 1308 interaction interaction NN 1309 1313 with with IN 1314 1317 DNA DNA NNP 1318 1321 and and CC 1322 1326 that that IN 1327 1330 Rel Rel NNP 1331 1334 can can MD 1335 1337 be be VB 1338 1339 a a DT 1340 1346 potent potent JJ 1347 1362 transcriptional transcriptional JJ 1363 1372 activator activator NN 1373 1375 on on IN 1376 1384 specific specific JJ 1385 1390 kappa kappa NN 1391 1392 B b NN 1393 1398 sites site NNS 1398 1399 . . .